In this article, San Francisco, known for its tech workers in hoodies, hosted thousands of executives in suits for JPMorgan’s annual health-care conference. Leaders from various health systems, venture capital firms, and companies worldwide gathered in hotel lobbies to discuss business and strategies for 2025. The conference took place following the tragic death of UnitedHealthcare CEO Brian Thompson, sparking social media posts criticizing the health-care industry.
Several companies, including Cigna and Walgreens, withdrew from the conference, citing safety concerns. The event saw heightened security measures, with a significant police presence at the main venue, the Westin St. Francis Hotel. Discussions at the conference revolved around the implications of Thompson’s death on the industry and the need for transformation and responsibility.
Despite the somber atmosphere, there was excitement about advancements in health care, such as artificial intelligence and weight loss drugs like GLP-1s. Companies showcased AI tools aimed at streamlining administrative tasks in health care. Nvidia, a key player in AI hardware, announced partnerships with various health-care organizations, signaling growth in AI applications.
Executives at the conference also discussed the benefits of GLP-1 drugs in weight loss and potential treatments for other conditions. The industry faces challenges such as supply shortages and high costs, but there is optimism about the drugs’ impact on public health. Uncertainty loomed over the sector due to unanswered questions about the incoming Trump administration’s health-care policies.
Amidst the uncertainty, executives expressed hope for increased access to care and transparency in pricing under the new administration. The market’s volatility and future outlook were topics of discussion among health-care industry leaders at the conference.
